Analysis of blood-based liquid biopsies in prostate cancer. Examples of...
Analysis of blood-based liquid biopsies in prostate cancer. Examples of molecular analyses enabled by the isolation of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and tumor-derived exosomes, are illustrated. Abbreviations: mCRPC: metastatic castration-resistant prostate cancer; cfDNA: cell-free circulating DNA.

Image source: Bonfil RD, Al-Eyd G, Oncoscience 2023 (CC BY 4.0)

News • CTC, ctDNA and exosomes in PCa management

Prostate cancer: Blood-based liquid biopsies yield valuable information

During the last decade, blood sampling of cancer patients aimed at analyzing the presence of cells, membrane-bound vesicles, or molecules released by primary tumors or metastatic growths emerged as an alternative to traditional tissue biopsies.

The advent of this minimally invasive approach, known as blood-based liquid biopsy, began to play a pivotal role in the management of diverse cancers, establishing itself as a vital component of precision medicine. In the new paper, published in Oncoscience, researchers R. Daniel Bonfil and Ghaith Al-Eyd from Nova Southeastern University discuss three blood-based liquid biopsies, namely circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and tumor-derived exosomes, as they relate to prostate cancer (PCa) management. “In this research perspective, we present a comprehensive overview of the recent advances related to the clinical significance of blood-based liquid biopsies in PCa, with a primary emphasis placed on key biomarkers such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes.”

With the assistance of artificial intelligence based on pre-established parameters, the utilization of blood-based liquid biopsies will soon enhance the stratification of PCa patients and facilitate timely therapeutic decision making

R. Daniel Bonfil, Ghaith Al-Eyd

The advances achieved in the molecular characterization of these types of liquid biopsies and their potential to predict recurrence, improve responses to certain treatments, and evaluate prognosis, in PCa patients, are highlighted herein. While there is currently full clinical validation for only one CTC-based and one ctDNA-based liquid biopsy for patients with metastatic castration-resistant PCa, the adoption of additional methods is anticipated as they undergo standardization and achieve analytical and clinical validation. Advantages and disadvantages of different blood-based liquid biopsy approaches in the context of PCa are outlined in this paper, while also considering potential synergies through combinatory strategies. “We anticipate that, with the assistance of artificial intelligence based on pre-established parameters, the utilization of blood-based liquid biopsies will soon enhance the stratification of PCa patients and facilitate timely therapeutic decision making.” 


Source: Impact Journals, LLC

11.12.2023

Read all latest stories

Related articles

Photo

News • Biomarker from blood test

Lung cancer: Liquid biopsy accurately predicts immunotherapy response

A simple blood test could be a better predictor of whether cancer immunotherapy will be successful for a patient with lung cancer than an invasive tumor biopsy procedure.

Photo

News • BRCA and prostate, pancreatic cancers

Faulty 'breast cancer gene' BRCA also dangerous for men

Faulty versions of the BRCA1 and BRCA2 genes are well known to increase the risk of breast and ovarian cancer. Now, they have been linked to several other cancers, including those that affect men.

Photo

News • Oncology early detection tool

Blood test for 50+ types of cancer promising for screening

Final results from a study of a blood test that can detect more than 50 types of cancer have shown that it is accurate enough to be rolled out as a multi-cancer screening test among people at higher…

Related products

Subscribe to Newsletter